Claude

The Numbers

MetLife trades at $73.88, a 15.7x trailing P/E and just 8.2x forward earnings – a discount that reflects the market pricing in insurance cycle risk despite the company delivering 10% adjusted EPS growth in FY2025 and a 16% adjusted ROE, squarely within its "New Frontier" strategic targets. The single metric most likely to rerate the stock is whether MetLife can sustain its adjusted ROE above 15% through FY2026-2027 while maintaining buyback intensity.

The analyst consensus target of $90.06 implies 22% upside from current levels. 12 of 18 analysts rate MET Buy or Strong Buy, with zero Sells. Wells Fargo recently lowered its target to $90 but maintained Overweight; Evercore ISI raised its target to $96; UBS has a Buy at $102.

Price Action

MET peaked at $83.25 in mid-December 2025 and has since corrected 11%, driven by broader market volatility rather than company-specific factors. The stock found support near $67.33 (the 52-week low) in late March and has bounced. It currently sits 7% below its 200-day moving average of $77.48, suggesting room for mean-reversion if macro fear abates.

Revenue & Earnings Power

Revenue grew 8.6% in FY2025 to $77.1B, driven by strong premiums, fees, and other revenues (PFOs) which reached $57.6B (+10%). However, GAAP net income fell to $3.4B from $4.4B, largely due to investment-related mark-to-market noise and actuarial assumption updates. Adjusted earnings – the metric management and analysts focus on – rose 10% to $8.89 per share.

Q4 2025 revenue spiked to $23.8B, likely driven by pension risk transfer (PRT) activity and investment gains. Net income in Q4 was $809M versus $1,271M a year earlier, reflecting the gap between GAAP results and underlying operating performance. Adjusted Q4 EPS of $2.49 beat consensus by 5.5%.

Earnings Surprises

MetLife has had a mixed earnings surprise record over the past two years: four beats, two misses, and two near-in-line quarters. The two misses (Q3 2024 at -10.6% and Q2 2025 at -6.5%) triggered brief sell-offs. The second half of FY2025 showed improving execution with consecutive beats, which matters for sentiment.

EPS Trajectory

EPS has compounded at ~8% annually since FY2017. The FY2021 spike ($9.13) reflected favorable variable investment income and reserve releases; the FY2022 dip was driven by LDTI accounting adoption and market declines. The FY2024-2025 ramp shows underlying earnings power recovering. Adjusted EPS of $8.89 in FY2025 is the more relevant figure – it excludes notable items and represents a 10% increase year-over-year.

Cash Generation & Capital Return

MetLife returned $5.6B to shareholders in FY2025 ($1.7B dividends + $3.9B buybacks), consuming 31% of operating cash flow. The company approved a new $3B buyback authorization and raised its quarterly dividend 4.1% to $0.5675 per share. Share count has declined from 913M (FY2020) to 652M today – a 29% reduction in six years, representing one of the most aggressive buyback programs in life insurance.

Share Count Reduction

The relentless buyback has been a key EPS growth driver. Even in years when net income was flat or down (FY2022-2023), EPS continued rising because of the shrinking share count. At the current buyback pace (~$3-4B/year), shares outstanding will drop below 600M by FY2027, providing a built-in EPS tailwind of roughly 5-6% annually.

Balance Sheet & Leverage

Total debt rose modestly to $20.2B in FY2025 from $18.7B, while equity held at $28.4B. The debt-to-equity ratio of 0.71x is manageable for a life insurer. The equity decline from $74.6B (FY2020) to $28.4B is largely an accounting artifact – LDTI adoption and AOCI swings from rising rates destroyed reported book value, but tangible book excluding AOCI is much higher. Book value per share stands at $43.33, with the stock trading at 1.7x book.

The jump in the debt-to-equity ratio from 0.26x to 0.60x in FY2022 was driven entirely by the equity denominator collapsing under AOCI losses, not by debt growth. Actual financial debt has only grown from $17.4B to $20.2B over five years.

Return on Equity

GAAP ROE is noisy due to accounting changes and AOCI swings. The more meaningful figure is adjusted ROE, which MetLife reported at 16% for FY2025 (with Q4 hitting 17.6%), squarely within the New Frontier target of 15-17%. This is the metric most likely to drive multiple expansion if sustained.

Peer Comparison

MetLife trades at a premium to Prudential and Lincoln on both trailing and forward P/E, reflecting its higher ROE and more diversified business. Aflac commands a higher multiple due to its higher margins and ROE (supplemental insurance is more profitable than traditional life). MET's forward P/E of 8.2x suggests the market expects earnings growth to continue – analyst consensus projects $9.80 adjusted EPS for FY2026.

Valuation Context

At $73.88, MET trades at the low end of analyst targets and near the lowest Wall Street estimate of $73. Applying a modest 10x multiple to the $9.80 consensus FY2026 EPS yields a ~$98 fair value. Even at a conservative 8x, the stock is roughly fairly valued. The market appears to be pricing in either earnings risk or a macro downturn that compresses insurance demand.

Operating Margins

GAAP margins are heavily influenced by investment gains/losses and actuarial reserve changes, making year-to-year comparisons unreliable. FY2023's margin collapse reflected a large reserve charge, not operational deterioration. The more stable adjusted operating margin is what management targets. What matters: FY2025 adjusted pre-tax operating earnings rose to $6.7B, a meaningful improvement over FY2024.

Cash Flow vs Net Income

Operating cash flow has grown every year since FY2020, rising from $11.6B to $18.1B, regardless of GAAP net income volatility. This is the hallmark of a life insurance model: premium cash flows are highly predictable even when accounting results swing on investment marks and reserve assumptions. The growing spread between OCF and net income in FY2023-2025 is not a red flag – it reflects non-cash charges that do not impair cash generation.

Closing Assessment

The numbers confirm MetLife is executing on its New Frontier strategy: 10% adjusted EPS growth, 16% adjusted ROE, and $5.6B in shareholder returns in FY2025. The stock's current discount to analyst targets and its own historical multiple likely reflects macro caution rather than fundamental deterioration. The numbers contradict any thesis that MetLife is in secular decline – operating cash flow, adjusted earnings, and capital return are all at multi-year highs. Watch next quarter for whether PFO growth (ex-PRT) sustains above 5% and whether adjusted ROE holds above 15%. Any slippage on ROE would validate the current discount.